SA Cannistra - New England Journal of Medicine, 2004 - Mass Medical Soc
Patients with ovarian cancer usually present with advanced disease, and the disease is generally managed with surgical resection followed by platinum-based chemotherapy …
K Alsop, S Fereday, C Meldrum, A DeFazio… - Journal of clinical …, 2012 - ascopubs.org
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line mutation on …
N Mavaddat, D Barrowdale, IL Andrulis… - … Biomarkers & Prevention, 2012 - AACR
Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further …
EC Halperin, LW Brady, CA Perez, DE Wazer - 2013 - books.google.com
Inside the Sixth Edition of this now-classic reference, you will discover encyclopedic coverage of topics ranging from basic science to sophisticated computer-based radiation …
Context Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results. Objective To determine the relationships between …
KR Cho, IM Shih - Annual review of pathology: mechanisms of …, 2009 - annualreviews.org
Ovarian carcinomas are a heterogeneous group of neoplasms and are traditionally subclassified based on type and degree of differentiation. Although current clinical …
Ovarian cancer varies widely in frequency among different geographic regions and ethnic groups, with a high incidence in Northern Europe and the United States, and a low …
Background: BRCA1 and BRCA2 mutations in general populations and in various types of cancers have not been well characterized. We investigated the presence of these mutations …
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 …